United States · Bill · S
S. 3633 (110th)
Transparency in Drug Labeling Act
Introduced
26 September 2008
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
14 August 2025
Summary
Transparency in Drug Labeling Act - Amends the Federal Food, Drug, and Cosmetic Act to deem a drug to be misbranded unless the labeling of such drug lists the identity of the country of manufacture of each active ingredient and each inactive ingredient of the drug, listed in descending order based on the percentage of the number of such ingredients in the final dosage form manufactured in such countries.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 26 September 2008
Introduced in Senate (PDF)
Introduced in Senate · EN · 26 September 2008
Introduced in Senate
summary · EN · 26 September 2008
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/110th-congress/senate-bill/3633
- Open data entity: https://api.congress.gov/v3/bill/110/s/3633